BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $260.00 price target on Biogen (NASDAQ: BIIB), following the company's Q4 earnings report.

The analyst quotes: "Guidance represents a challenging set up for 2022—with expenses still too high by our view, and not supported by the revenue base. Despite limited access and negative provider sentiment, there appears to be some usage of Aduhelm with sales of $1M in 4Q21 and $3M for the FY."

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $224.96 yesterday.

Written by Vlad Schepkov | [email protected]